Read More

Boston Scientific’s Farapulse Eyes Stronger US Market Position With Potential FDA Approval

Boston Scientific Corp (NYSE: BSX) will present results from ADVENT pivotal trial for its Farapulse Pulsed Field Ablation (PFA) system at the 2023 European Society of Cardiology Congress on 27 August. ADVENT is a randomized clinical trial comparing Farapulse PFA to thermal ablation. 

ABT